Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL therapy in advanced solid tumors
NCT06488950Phase 1Recruiting
- Sponsor
- Juncell Therapeutics
- Start
- Apr 2023
- Primary completion
- Jun 2026
- Modality
- Gene Editing, Gene Silencing, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of GC203 in solid tumor (advanced stage) (2 arms), sponsored by Juncell Therapeutics. Primary endpoint: Adverse Events at 6 months. Started Apr 2023; status: recruiting.
02
Drugs
GC203
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06488950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06488950.